Guardian featured Harley Street IBS & Autoimmune Clinic has welcomed many beautiful individuals experiencing all forms of hair loss (Alopecia). Our Alopecia treatment uses a functional medicine approach. A requirement for this dedicated and specialist clinic became abundantly clear following the frustrations Alopecia patients spoke of prior to being treated at our clinic.
Patients spoke of the lack of support they had received previously in their alopecia treatment; the hurtful diagnosis they had been given that their hair would never grow back; they spoke of their shame, their depression, their loss of identity as well as the social paranoia; and the inconvenience and itchiness of very expensive wigs.
Alopecia is usually caused by a problem with the immune system. It’s more common among people with other autoimmune conditions. Natural Medicine is usually very effective at treating Alopecia and results can be seen as the body responds to the Alopecia treatment and hair growth is stimulated.
We use diagnostic Functional Medicine testing to investigate and determine the cause of each individual’s hair loss or Alopecia areata. Natural medicine, which is licensed by the UK Government’s Department of Health, is then given to the patient to help bring the body back into equilibrium and to ultimately modulate immune function. Each prescription is prepared and dispensed to meet the unique needs of each patient. Our patients find that this natural and gentle approach works best in Alopecia treatment and clear results can usually be seen through the subsequent hair regrowth. We do not have a one size fits all approach.
In addition, we address the psychological impact Alopecia has on the person as it is a condition which not only clearly effects the body, but takes a silent hefty toll on the psyche too. Every prescription is made to also address symptoms ranging from depression to paranoia, to stress and adrenal exhaustion. Patients report feeling more like their old self.
Following Alopecia treatment, patients speak of regaining their lost sense of identity, of being given hope and encouragement as they watch, over time, the regrowth of their hair.
This holistic approach also usually works well for treating any gut issues or IBS symptoms which are so often associated with alopecia and other autoimmune conditions; hence many of these related symptoms also dissipate or disappear too as the body is brought back to its equilibrium.
Sato-Kawamura M, Aiba S, Tagami H. Strong expression of CD40, CD54 and HLA-DR antigen and lack of evidence for direct cellular cytotoxicity are unique immunohistopathological features in alopecia areata. Archives of Dermatological Research. 2003;294(12):536–543. [PubMed] [Google Scholar]
Arca E, Muşabak U, Akar A, Erbil AH, Taştan HB. Interferon-gamma in alopecia areata. European Journal of Dermatology. 2004;14(1):33–36. [PubMed] [Google Scholar]
Deeths MJ, Endrizzi BT, Irvin ML, Steiner LP, Ericson ME, Hordinsky MK. Phenotypic analysis of T-cells in extensive alopecia areata scalp suggests partial tolerance. Journal of Investigative Dermatology. 2006;126(2):366–373. [PubMed] [Google Scholar]
Kuwano Y, Fujimoto M, Watanabe R, et al. Serum chemokine profiles in patients with alopecia areata. British Journal of Dermatology. 2007;157(3):466–473. [PubMed] [Google Scholar]
Kim HS, Cho DH, Kim HJ, Lee JY, Cho BK, Park HJ. Immunoreactivity of corticotropin-releasing hormone, adrenocorticotropic hormone and α-melanocyte-stimulating hormone in alopecia areata. Experimental Dermatology. 2006;15(7):515–522. [PubMed] [Google Scholar]
Kuwano Y, Fujimoto M, Watanabe R, et al. Serum BAFF and APRIL levels in patients with alopecia areata. Journal of Dermatological Science. 2008;50(3):236–239. [PubMed] [Google Scholar]
Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annual Review of Immunology. 2003;21:231–264. [PubMed] [Google Scholar]
Mackay F, Leung H. The role of the BAFF/APRIL system on T cell function. Seminars in Immunology. 2006;18(5):284–289. [PubMed] [Google Scholar]
Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. Journal of Investigative Dermatology Symposium Proceedings. 2003;8(2):188–194. [PubMed] [Google Scholar]
Christoph T, Müller-Röver S, Audring H, et al. The human hair follicle immune system: cellular composition and immune privilege. British Journal of Dermatology. 2000;142(5):862–873. [PubMed] [Google Scholar]
Zöller M, McElwee KJ, Vitacolonna M, Hoffmann R. Apoptosis resistance in peripheral blood lymphocytes of alopecia areata patients. Journal of Autoimmunity. 2004;23(3):241–256. [PubMed] [Google Scholar]
Shimizu T, Mizue Y, Abe R, Watanabe H, Shimizu H. Increased macrophage migration inhibitory factor (MIF) in the sera of patients with extensive alopecia areata. Journal of Investigative Dermatology. 2002;118(3):555–557. [PubMed] [Google Scholar]
Shimizu T, Hizawa N, Honda A, et al. Promoter region polymorphism of macrophage migration inhibitory factor is string risk factor for young onset of extensive alopecia areata. Genes and Immunity. 2005;6(4):285–289. [PubMed] [Google Scholar]
Zhang X, Yu M, Yu W, Weinberg J, Shapiro J, McElwee KJ. Development of alopecia areata is associated with higher central and peripheral hypothalamic-pituitary-adrenal tone in the skin graft induced C3H/HeJ mouse model. Journal of Investigative Dermatology. 2009;129(6):1527–1538. [PMC free article] [PubMed] [Google Scholar]
Gupta P, Freyschmidt-Paul P, Vitacolonna M, et al. A chronic contact eczema impedes migration of antigen-presenting cells in alopecia areata. Journal of Investigative Dermatology. 2006;126(7):1559–1573. [PubMed] [Google Scholar]
Herbst V, Zöller M, Kissling S, Wenzel E, Stutz N, Freyschmidt-Paul P. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. European Journal of Dermatology. 2006;16(5):537–542. [PubMed] [Google Scholar]
Pan Y, Rao NA. Alopecia areata during etanercept therapy. Ocular Immunology and Inflammation. 2009;17(2):127–129. [PubMed] [Google Scholar]
Posten W, Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Archives of Dermatology. 2005;141(6):759–760. [PubMed] [Google Scholar]